Amylyx Pharmaceuticals, the maker of Relyvrio, a drug intended to treat Lou Gehrig’s disease (amyotrophic lateral sclerosis or ALS), announced on Thursday its decision to pull the medication from the market. This move comes after the drug failed to demonstrate efficacy in a large clinical study, marking a significant setback for ALS patients and advocates. … Read more